SRRM4 Inhibitors

SRRM4 Inhibitors encompass a range of chemicals that influence the activity of SRRM4, particularly in its role in alternative splicing and neurodevelopmental processes. These inhibitors target various cellular mechanisms and pathways, thereby affecting SRRM4 function. The primary mode of inhibition comes from targeting the spliceosome, a complex vital for splicing RNA. Chemicals like Pladienolide B, E7107, H3B-8800, Spliceostatin A, Meayamycin B, and Tetrocarcin A work by disrupting the normal function of the spliceosome. Since SRRM4 plays a role in alternative splicing, affecting the spliceosome can indirectly influence SRRM4-mediated splicing events. These inhibitors typically bind to essential components of the spliceosome, like the SF3b complex, and inhibit its function, leading to altered splicing patterns that can affect various biological processes, including those governed by SRRM4. Other compounds like Indisulam (E7070) work by inducing the degradation of proteins like RBM39, which are crucial for splicing. By disrupting these proteins, Indisulam impacts the splicing machinery, potentially influencing SRRM4's activity.

In addition to spliceosome-targeting agents, compounds like Chloroquine, Quercetin, Rapamycin, and LY341495 exert broader effects on cellular pathways. Chloroquine affects endosomal pathways, Quercetin has multiple cellular targets due to its antioxidant properties, Rapamycin inhibits the mTOR pathway affecting cellular growth and proliferation, and LY341495 acts on neural pathways by antagonizing metabotropic glutamate receptors. These broader actions can influence cellular environments and pathways in which SRRM4 operates. While these chemicals do not directly target SRRM4, their impact on related pathways and processes can indirectly modulate the activity of SRRM4, particularly in its role in alternative splicing.